Hat Worn by Napoleon Fetches $1.6 Million at Auction

Raphael Pitchal, left, and Jean Christophe Chataignier of Osenat's auction house remove the protection of one of the signature broad, black hats that Napoléon wore when he ruled 19th century France and waged war in Europe at Osenat's auction house in Fontainebleau, south of Paris, Friday, Nov. 17, 2023. (AP Photo/Christophe Ena)
Raphael Pitchal, left, and Jean Christophe Chataignier of Osenat's auction house remove the protection of one of the signature broad, black hats that Napoléon wore when he ruled 19th century France and waged war in Europe at Osenat's auction house in Fontainebleau, south of Paris, Friday, Nov. 17, 2023. (AP Photo/Christophe Ena)
TT

Hat Worn by Napoleon Fetches $1.6 Million at Auction

Raphael Pitchal, left, and Jean Christophe Chataignier of Osenat's auction house remove the protection of one of the signature broad, black hats that Napoléon wore when he ruled 19th century France and waged war in Europe at Osenat's auction house in Fontainebleau, south of Paris, Friday, Nov. 17, 2023. (AP Photo/Christophe Ena)
Raphael Pitchal, left, and Jean Christophe Chataignier of Osenat's auction house remove the protection of one of the signature broad, black hats that Napoléon wore when he ruled 19th century France and waged war in Europe at Osenat's auction house in Fontainebleau, south of Paris, Friday, Nov. 17, 2023. (AP Photo/Christophe Ena)

A faded and cracked felt hat worn by Napoléon Bonaparte fetched $1.6 million at an auction Sunday of the French emperor’s belongings
Yes, $1.6 million.
The signature broad, black hat — one of a handful still in existence that Napoléon wore when he ruled 19th century France and waged war in Europe — was initially valued at 600,000 to 800,000 euros ($650,000-870,000). It was the centerpiece of Sunday's auction in Fontainebleau of memorabilia collected by a French industrialist who died last year, The Associated Press reported.
But the bidding quickly jumped higher and higher until Jean Pierre Osenat, president of the Osenat auction house, designated the winner.
‘’We are at 1.5 million (euros) for Napoleon’s hat ... for this major symbol of the Napoleonic epoch,'' he said. The name of the winning bidder was not released.
While other officers customarily wore their hats with the wings facing front to back, Napoléon wore his with the ends pointing toward his shoulders. The style — known as “en bataille,” or in battle — made it easier for his troops to spot their leader in combat.
The hat on sale was first recovered by Col. Pierre Baillon, a quartermaster under Napoléon, according to the auctioneers. The hat then passed through many hands before industrialist Jean-Louis Noisiez acquired it.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”